ArticleVirus genes2026
Characterization of human parainfluenza virus type 2 circulating in southern France between 2017 and 2022 using whole-genome sequencing.
Article in Virus genes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Genomic surveillance of respiratory viruses is an expanding field. As of 2024, only 110 (near-) complete genomes of human parainfluenza virus type 2 (HPIV2) were available in GenBank, none being from France. Here we aimed to obtain and analyze HPIV2 genomes from residues of HPIV2 RNA-positive respiratory samples from patients diagnosed in university hospitals of Marseille, Southern France, between 2017 and 2022. Prior to next-generation sequencing (NGS), an in-house PCR-based enrichment strategy was implemented with primers chosen with PrimalScheme. NGS used Illumina technology on a NovaSeq 6000 instrument. HPIV2 genomes were generated from NGS reads by mapping and de novo assembly using CLC Genomics. Mutations were identified by NextClade, and phylogeny was performed by MEGA and NextClade. Seventy-seven near-complete (≥ 90% coverage) genomes and 239 genomes with ≥ 70% coverage were recovered from 318 HPIV2 RNA-positive samples. Two major genotypes, G1a (n = 129 genomes) and G3 (110), were identified, and five subgenotypes, namely G1a.5 (n = 23 genomes), G1a.8 (68), G3.4 (4), G3.5 (7), and G3.7 (23), were newly proposed. Genotype-specific mutations were in the L gene (encoding RNA polymerase) for G1a (T14612A/T11981A/T12374C) and the hemagglutinin-neuraminidase-encoding gene for G3 (G8171A/A14057G/10367G). Subgenotype G3 was only detected in 2019. Subgenotype G1a was absent during the 2021-2022 winter, before becoming majority again during autumn 2022. Although preliminary, this work increased by 70% the number of HPIV2 genomes available worldwide and produced the first genomes from France. It shows an evolution of genotypes, with significant genetic diversity, and of their distribution. It justifies the genomic surveillance of this virus.
Indexed as
Identifiers
41396244What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.